NPS Pharmaceuticals — Merger or Acquisition (May 2003)
8 slides from NPS Pharmaceuticals's merger presentation, May 2, 2003
Slide 1: Science, Pipeline, Products: Creating a Biotechnology Leader
Science, Pipeline, Products: Creating a Biotechnology Leader
Slide 2: To Build a Sustainable Top-Tier Biotech Based On
To Build a Sustainable Top-Tier Biotech Based On: • A deep, diversified and sustainable pipeline • A well defined pathway to profitability • A fully integrated infrastructure
Slide 3: Platform Technologies, Pipeline and Commercialization
Platform Technologies + PEGylation + PEG : Cytoxies + Inhaled NE Leupro Phase! Phase Il Preclinical Phase Ill + single-chain Antibodies Commercialization & Manufacturing + PEG-INTRON + ABELCET + ADAGEN + ONCASPAR * DEPOCYT NPS ™mm ENZON
Slide 4: PREOS for the Treatment of Osteoporosis
PREOS for the Treatment of Osteoporosis Proposed Indications and Usage
Slide 5: TOP Study: Overview of Clinical Trial Design
TOP Study Overview of Clinical Trial Design
Slide 6: POWER Study: Overview of Clinical Trial Designs
POWER Study Overview of Clinical Trial Designs
Slide 7: OLES (Open Label Extension Study)
\- + =O “sole ” _ OLES (Open Label Extension Study)
Slide 8: Science, Pipeline, Products: Creating a Biotechnology Leader
Science, Pipeline, Products: Creating a Biotechnology Leader
NPS Pharmaceuticals — Merger or Acquisition (May 2003) on 6ix